Antiarrhythmic drugs for atrial fibrillation (Q33821199)

29 July 2017

1 reference

title

Antiarrhythmic drugs for atrial fibrillation (English)

1 reference

29 July 2017

1 reference

Alessandro Marinelli

1 reference

29 July 2017

Alessandro Capucci

series ordinal

1 reference

29 July 2017

language of work or name

English

0 references

publication date

17 February 2011

1 reference

full work available at URL

29 July 2017

http://www.informapharmascience.com/doi/abs/10.1517/14656566.2011.554400

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21323608

http://www.tandfonline.com/doi/pdf/10.1517/14656566.2011.554400

24 November 2024

1 reference

DOI

https://api.crossref.org/works/10.1517/14656566.2011.554400

Expert Opinion on Pharmacotherapy

24 November 2024

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

1201-1215

1 reference

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

A comparison of rate control and rhythm control in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Rhythm control versus rate control for atrial fibrillation and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Amiodarone as paradigm for developing new drugs for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Atrial-selective approaches for the treatment of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

The mechanism of atrial antiarrhythmic action of RSD1235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Atrial remodeling and atrial fibrillation: mechanisms and implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Electrical cardioversion of atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Intravenous propafenone for converting recent onset atrial fibrillation in emergency departments: a randomized placebo-controlled multicenter trial. FAPS Investigators Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Amiodarone versus sotalol for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Clinical safety profile of sotalol in patients with arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Pharmacological cardioversion of atrial fibrillation: current management and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Increased mortality after dronedarone therapy for severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Effect of dronedarone on cardiovascular events in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Usefulness of Vernakalant Hydrochloride Injection for Rapid Conversion of Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Lenient versus strict rate control in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.554400

Cochrane Database of Systematic Reviews

21 January 2018

CD005049

Lafuente-Lafuente C

2007

1 reference

DOI

https://api.crossref.org/works/10.1517/14656566.2011.554400

Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators.

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Efficacy of amiodarone for the termination of persistent atrial fibrillation

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Effect of dronedarone on renal function in healthy subjects.

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less

24 November 2024

1 reference

https://api.crossref.org/works/10.1517/14656566.2011.554400

24 November 2024

Identifiers

DOI

1 reference

29 July 2017

1 reference